Michael Peluso, MD

Infectious disease doctor @UCSF. #LongCOVID researcher. #HIV clinician and #HIVcure researcher.

[Michael Peluso, MD @MichaelPelusoMD]

Abstract deadline for 3rd International #LongCOVID Meeting is coming up - it is a privilege to be on the organizing committee and I am really looking forward to this meeting!

https://t.co/QGVg1095tm

[Michael Peluso, MD @MichaelPelusoMD]

Proud to have been a part of this @polybioRF effort to describe the path forward for #LongCOVID trials targeting SARS-CoV-2 persistence. We need a robust biomarker development program and to launch more trials to rigorously test treatments that target these pathways now.

[PolyBio @polybioRF]

BREAKING: Cutting-edge Recommendations Provide Treatment Path for Millions of Long COVID patients 💊

In a new report global experts outline key considerations to address persistent SARS-CoV-2; provide a roadmap to test critical new long COVID therapies: https://t.co/FKKdKtveS2

[Michael Peluso, MD @MichaelPelusoMD]

New @UCSF #LIINC paper shows low mature/cytotoxic NK cells in #LongCovid compared to full recovery. Could reflect inability to clear infection. More interesting data showing immunologic differences in #LongCovid. Thanks to @polybioRF @NIH for funding.

https://t.co/HoHSpuS3Xv

[Michael Peluso, MD @MichaelPelusoMD]

Excited to share this @ScienceTM viewpoint with @DrMaureenHanson on why #LongCOVID #MECFS and other infection-associated chronic conditions should be studied together as part of a coordinated research agenda.

https://t.co/rJLSuO59Wh

[Michael Peluso, MD @MichaelPelusoMD]

Realizing I forgot the link which is here: https://t.co/nBRATXwqxx

[Michael Peluso, MD @MichaelPelusoMD]

Lots of attention on cortisol in #LongCovid lately. Here are results from a pilot project in the @UCSF #LIINC cohort. Similar levels between LC and recovered, but morning dynamics appear to differ, esp. in those with post-COVID ME/CFS. Detailed follow up project ongoing.

[Michael Peluso, MD @MichaelPelusoMD]

New @CMIJournal study showing association between post-acute SARS-CoV-2 protein in blood and #LongCOVID. Data from 4 cohorts, including #NIHRECOVER and @UCSF #LIINC. Need more research ASAP to see if useful as a biomarker for trials!

[WesElyMD @WesElyMD]

Long Covid Research 💰💰

In our @NatureIndex piece, @MichaelPelusoMD & I expound on different funding avenues for #brainfog…and the dire need for science + answers.

Thx to @BecCrew for her wisdom & insight as editor.

Read here:
https://t.co/wNy60zJjIA

[Michael Peluso, MD @MichaelPelusoMD]

Excited to be visiting @VirusesImmunity at the 2nd @YaleCII symposium today to talk about #LongCovid - Where we are, where we need to go, and how we can get there.

[Michael Peluso, MD @MichaelPelusoMD]

Excellent commentary from @patientled in Cell outlining priorities for #LongCOVID research.

https://t.co/5gSMxzwoQb

[Michael Peluso, MD @MichaelPelusoMD]

Our mechanistic review of #LongCovid - published in @CellCellPress - hopefully will be helpful coming out of the very inspiring RECOVER-Treating Long COVID meeting this week.

Excited for the progress we will make together in the next year!

https://t.co/JUYQnXYRlO

[Michael Peluso, MD @MichaelPelusoMD]

Our new @UCSF #FindCOVID/#LIINC paper in @NatureComms showing SCV2 burden in first 3 weeks of COVID predicts future #LongCovid.

In addition to LC treatment trials, we need investment in studies to prevent LC! Zero US-based trials on prevention so far.

https://t.co/mT0cLdySV8

[Patient-Led Research Collaborative @patientled]

Today, we are thrilled to see the introduction of The Long COVID Research Moonshot Act by Senator Bernie Sanders (@SenSanders), co-sponsored by Senators @SenTimKaine, @SenDuckworth, @SenMarkey, @SenPeterWelch, and @SenTinaSmith!

https://t.co/P24hWEmTNL

#LongCovid 1/

[PolyBio @polybioRF]

Breaking!: Research published today in Science Translational Medicine and supported by PolyBio Research Foundation shows that the #SARS-CoV-2 virus can chronically persist in the gut of patients with long COVID for over 2 years: https://t.co/rYAT9BHKqe

[Michael Peluso, MD @MichaelPelusoMD]

New @UCSF #LIINC paper: immune activation & viral persistence in tissue up to 2 years post-COVID. Found double-stranded RNA in #LongCOVID, suggesting active reservoir persists and evades immune clearance. Thanks @polybioRF, @NIH for support. @ScienceTM

https://t.co/30Eb0juBN7

[Michael Peluso, MD @MichaelPelusoMD]

To quote the paper: "The landscape of PASC research is dynamic. Smaller studies that are more focused and agile can scout the terrain ahead of larger and more definitive studies."

With each of these studies, the path will become a bit clearer. Let's keep up the momentum!

[Michael Peluso, MD @MichaelPelusoMD]

Today, the #Stanford #Paxlovid trial for #LongCOVID (STOP-PASC) reported no difference in patient reported outcomes between drug vs placebo.

Headlines say it's "negative," some are saying we should abandon the virus persistence hypothesis. My take:

https://t.co/kY6ifkpq83

[Michael Peluso, MD @MichaelPelusoMD]

7) This was not a home run. But a great rally (and a big win) often starts with getting the leadoff hitter onto first - putting the rest of the lineup in position to build on that success. Science is the same way - early base hits eventually get you a win by building momentum.